DrugPatentWatch Database Preview
Deflazacort - Generic Drug Details
What are the generic sources for deflazacort and what is the scope of patent protection?
Deflazacort
is the generic ingredient in one branded drug marketed by Ptc Therap and is included in two NDAs. Additional information is available in the individual branded drug profile pages.There are three drug master file entries for deflazacort. Two suppliers are listed for this compound.
Summary for deflazacort
| US Patents: | 0 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 2 |
| Drug Master File Entries: | 3 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 59 |
| Clinical Trials: | 19 |
| Patent Applications: | 4,800 |
| DailyMed Link: | deflazacort at DailyMed |
Recent Clinical Trials for deflazacort
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Postgraduate Institute of Medical Education and Research | Phase 2/Phase 3 |
| Northwestern University | Phase 2 |
| PTC Therapeutics | Phase 3 |
Pharmacology for deflazacort
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Synonyms for deflazacort
| (11beta,16beta)-21-(Acetyloxy)-11-hydroxy-2'-methyl-5'H-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione |
| (11beta,16beta)-21-(acetyloxy)-11-hydroxy-2'-methyl-5'H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione |
| 11b,21-Dihydroxy-2'-methyl-5'bH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 21-acetate |
| 11beta,21-Dihydroxy-2'-methyl-5'betaH-pregna-1,4-dieno(17,16-d)oxazole-3,20-dione 21-acetate |
| 11beta,21-dihydroxy-2'-methyl-5'betaH-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione 2'-acetate |
| 14484-47-0 |
| 2-((6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-6a,8a,10-trimethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d]oxazol-8b-yl)-2-oxoethyl acetate |
| 2-((6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-6a,8a,10-trimethyl-4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d]oxazol-8b-yl)-2-oxoethyl acetate |
| 2-[(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-4a,6a,8-trimethyl-2-oxo-2,4a,4b,5,6,6a,9a,10,10a,10b,11,12-dodecahydro-6bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]oxazol-6b-yl]-2-oxoethyl acetate |
| 484D470 |
| 5'-beta-H-Pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 11-beta,21-dihydroxy-2'-methyl-, 21-acetate |
| 5'H-Pregna-1,4-dieno(17,16-d)oxazole-3,20-dione, 21-(acetyloxy)-11-hydroxy-2'-methyl-, (11beta,16beta)- |
| AB01274724_02 |
| AB01274724-01 |
| AB2000350 |
| ACN-043364 |
| AKOS015895199 |
| Azacort |
| BBL036672 |
| BCP08474 |
| C-22370 |
| C25H31NO6 |
| Calcort |
| CAS-14484-47-0 |
| CC-26308 |
| CCG-220817 |
| CHEBI:135720 |
| CHEMBL1201891 |
| Cortax |
| Cortax;Decortil;Deflanil;Calcort |
| CS-2349 |
| D03671 |
| D4523 |
| DB11921 |
| Decortil |
| Deflan |
| Deflanil |
| Deflazacor |
| Deflazacort (Calcort) |
| Deflazacort (USAN/INN) |
| Deflazacort [USAN:INN:BAN] |
| Deflazacort, >=98% (HPLC) |
| Deflazacort, United States Pharmacopeia (USP) Reference Standard |
| Deflazacortum |
| Deflazacortum [INN-Latin] |
| Dezacor |
| DL-458-IT |
| DL-458IT |
| DSSTox_CID_378 |
| DSSTox_GSID_20378 |
| DSSTox_RID_75552 |
| DTXSID9020378 |
| EINECS 238-483-7 |
| Emflaza |
| Emflaza (TN) |
| Enzocort |
| Flantadin |
| GTPL9477 |
| H894 |
| HMS3714D15 |
| HY-13609 |
| KR5YZ6AE4B |
| KS-1158 |
| L-5458 |
| Lantadin |
| MDL 458 |
| MDL-458 |
| MFCD00866106 |
| NCGC00255189-01 |
| NCGC00263521-01 |
| Oxazacort |
| pregna-1,4-diene-11beta,21-diol-3,20-dione[17alpha,16alpha-d]-2'-methyloxazoline 21-acetate |
| Q-101371 |
| Q779118 |
| s1888 |
| SCHEMBL4018 |
| STL559051 |
| Tox21_112506 |
| Tox21_112506_1 |
| Tox21_301415 |
| UNII-KR5YZ6AE4B |
| ZINC4212809 |
US Patents and Regulatory Information for deflazacort
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-003 | Feb 9, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-001 | Feb 9, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-001 | Feb 9, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-002 | Feb 9, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Ptc Therap | EMFLAZA | deflazacort | TABLET;ORAL | 208684-002 | Feb 9, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Ptc Therap | EMFLAZA | deflazacort | SUSPENSION;ORAL | 208685-001 | Feb 9, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Ptc Therap | EMFLAZA | deflazacort | SUSPENSION;ORAL | 208685-001 | Feb 9, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
